Current Recommendations for the Treatment of Genital Herpes

Leung, D.T.; Sacks, S.L.
December 2000
Drugs;Dec2000, Vol. 60 Issue 6, p1329
Academic Journal
The incidence of genital herpes continues to increase in epidemic-like fashion. Aciclovir (acyclovir) has been the original gold standard of therapy. The recent addition of famciclovir and valaciclovir as antiherpes drugs has improved convenience as well as the efficacy of treatment. Although aciclovir remains a widely prescribed and reliable drug, its administration schedule falls short of the ease of usage that the newer nucleoside analogues offer, for both episodic and suppressive therapy. Suppression of symptomatic disease and asymptomatic shedding from the genitalia have both become popular approaches, if not the primary targets of antiviral therapy. Knowing that asymptomatic disease leads to most cases of transmission strongly suggests that suppression with antiviral agents could reduce transmission risk in discordant couples. Unfortunately, the role for antivirals in reducing transmission remains to be proven in clinical trials. Neonatal herpes is now successfully treated using aciclovir. Current randomised clinical trials are examining aciclovir and valaciclovir administration, as well as safety and efficacy for post-acute suppressive therapy. Prevention of recurrences in pregnancy is also a topic under investigation, with a view to reducing the medical need for Cesarean section, or alternatively (and far less likely to be accomplished) to protect the neonate. Although resistance is largely limited to the immunocompromised and a change in resistance patterns is not expected, several drugs are available for the treatment of aciclovir-resistant strains of herpes simplex. Foscarnet is the main alternative with proven efficacy in this setting. Unfortunately, administration of foscarnet requires intravenous therapy, although a single anecdote of topical foscarnet efficacy in this setting has been published. Alternatives include cidofovir gel, which is not commercially available but can be formulated locally from the intravenous preparation. Less effective alternatives include trifluridine and interferon. Future possibilities for treatment of genital herpes include a microparticle-based controlled-release formulation of aciclovir and resiquimod (VML-600; R-848). The search for an effective therapeutic vaccine for genital herpes has not been successful to date, although a live virus glycoprotein H-deficient (DISC) vaccine is currently in clinical trials. Recent data suggest that seronegative women are protected (albeit, not fully) by a glycoprotein D recombinant vaccine with adjuvant. Despite the established safety and convenience of current treatment options, better suppressive options and topical treatment options are much needed. Studies using existing agents as potential tools to avoid Cesarean section, or transmission to neonate or partner are ongoing. Both vaccines and antivirals may eventually play a role in prevention of infection.


Related Articles

  • Oral Famciclovir for the Suppression of Recurrent Genital Herpes: The Combined Data from Two Randomized Controlled Trials. Tyring, Stephen K.; Diaz-Mitoma, Francisco; Shafran, Stephen D.; Locke, Leslie A.; Sacks, Stephen L.; Young, Clarence L. // Journal of Cutaneous Medicine & Surgery;Nov/Dec2003, Vol. 7 Issue 6, p449 

    Background: Genital herpes is a very common sexually transmitted disease. Safe and effective therapies are needed for patients with frequent recurrences. Objective: The aim of our study was to determine the efficacy and safety of famciclovir for suppression of herpes simplex virus (HSV)...

  • Genital Herpes Simplex Virus Infection in the Adolescent: Special Considerations for Management. Stanberry, L.R.; Rosenthal, S.L. // Pediatric Drugs;2002, Vol. 4 Issue 5, p291 

    Genital herpes simplex virus (HSV) infections are increasingly common among adolescents. In developed countries, during the 1990s, adolescent HSV type 2 seroprevalence rates ranged from 4 to 30% depending on the population studied. The clinical diagnosis of genital herpes may be unreliable and...

  • The Topical Microbicide PRO 2000 Protects against Genital Herpes Infection in a Mouse Model. Bourne, Nigel; Bernstein, David I.; Ireland, James; Sonderfan, Andrew J.; Profy, Albert T.; Stanberry, Lawrence R. // Journal of Infectious Diseases;7/1/99, Vol. 180 Issue 1, p203 

    Examines the ability of naphthalene sulfonate polymer PRO 2000 both in solution and vaginal gel formulations to act as a topical microbicide against herpes simplex virus-2 infection in vivo in a mouse model of genital herpes. Protection offered by the gel against sexually transmitted disease;...

  • Acyclovir Topical.  // AHFS Consumer Medication Information;Aug2019, p1 

    Acyclovir cream is used to treat cold sores (fever blisters; blisters that are caused by a virus called herpes simplex) on the face or lips. Acyclovir ointment is used to treat first outbreaks of genital herpes (a herpes virus infection that causes sores to form around the genitals and rectum...

  • ASP2151 for the Treatment of Genital Herpes: A Randomized, Double-Blind, Placebo- and Valacyclovir-Controlled, Dose-Finding Study. Tyring, Stephen; Wald, Anna; Zadeikis, Neddie; Dhadda, Shobha; Takenouchi, Kazumasa; Rorig, Ramona // Journal of Infectious Diseases;4/1/2012, Vol. 205 Issue 7, p1100 

    Background. Current therapies for genital herpes have only partial efficacy. Helicase-primase inhibitors are novel, potent inhibitors of herpes simplex virus replication. Methods. This randomized trial assessed the safety and efficacy of ASP2151 for episodic therapy of recurrent genital herpes....

  • Looking at role of HSV serology. Azariah, Sunita // New Zealand Doctor;2/11/2009, p12 

    The article looks at the possible role of herpes simplex virus serology (HSV) in the management of genital herpes infection. Studies in countries show the unawareness of individuals of their seropositive status. Diagnosis of this sexually transmitted disease is done by taking a viral culture...

  • Lysine: Relief for herpes.  // Total Health;Oct94, Vol. 16 Issue 5, p46 

    Focuses on the herpes simplex virus (HSV). Symptoms of genital herpes; Danger posed by HSV to pregnant women, newborns and patients with impaired immunity; Role in the constriction of arterial blood vessels in patients who have undergone angioplasty; Effectiveness of lysine in the treatment of...

  • Two-Day Regimen of Acyclovir for Treatment of Recurrent Genital Herpes Simplex Virus Type 2 Infection. Wald, Anna; Carrell, David; Remington, Michael; Kexel, Elizabeth; Zeh, Judy; Corey, Lawrence // Clinical Infectious Diseases;4/1/2002, Vol. 34 Issue 7, p944 

    The standard course of antiviral therapy for recurrent genital herpes requires administration of multiple doses of medication for 5 days. To assess the efficacy of a shorter course of antiviral therapy, patients with recurrent genital herpes simplex virus type 2 (HSV-2) infection were enrolled...

  • Good news flowing at Allied.  // Australasian Biotechnology;Oct2013, Vol. 23 Issue 3, p41 

    The article reports on the approval of the products of Allied Healthcare Group, which include the Herpes Simplex Virus-2 (HSV-2) vaccine and CardioCel. It says that the biotechnology company Coridon, founded vt professor Ian Frazer in 2000, is developing the first-in-class for HSV-2,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics